Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease

Lucy M. Almers, James E. Graham, Peter J Havel, Douglas A. Corley

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background & Aims: Abdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin. Methods: We conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls. Results: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95% confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction <.01). Conclusions: Adiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.

Original languageEnglish (US)
Pages (from-to)2256-2264.e3
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number13
DOIs
StatePublished - Dec 1 2015

Fingerprint

Barrett Esophagus
Adiponectin
Gastroesophageal Reflux
Population Control
Molecular Weight
Odds Ratio
Confidence Intervals
Abdominal Obesity
Case-Control Studies
Adenocarcinoma
Body Mass Index
Hormones
Wounds and Injuries

Keywords

  • Adipokines
  • Adiponectin
  • Barrett's Esophagus
  • BMI
  • Esophageal Adenocarcinoma

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease. / Almers, Lucy M.; Graham, James E.; Havel, Peter J; Corley, Douglas A.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 13, 01.12.2015, p. 2256-2264.e3.

Research output: Contribution to journalArticle

Almers, Lucy M. ; Graham, James E. ; Havel, Peter J ; Corley, Douglas A. / Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease. In: Clinical Gastroenterology and Hepatology. 2015 ; Vol. 13, No. 13. pp. 2256-2264.e3.
@article{af8f77c49df742b7a47935602a48b84e,
title = "Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease",
abstract = "Background & Aims: Abdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin. Methods: We conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls. Results: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95{\%} confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95{\%} CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95{\%} CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction <.01). Conclusions: Adiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.",
keywords = "Adipokines, Adiponectin, Barrett's Esophagus, BMI, Esophageal Adenocarcinoma",
author = "Almers, {Lucy M.} and Graham, {James E.} and Havel, {Peter J} and Corley, {Douglas A.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.cgh.2015.01.009",
language = "English (US)",
volume = "13",
pages = "2256--2264.e3",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "13",

}

TY - JOUR

T1 - Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease

AU - Almers, Lucy M.

AU - Graham, James E.

AU - Havel, Peter J

AU - Corley, Douglas A.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background & Aims: Abdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin. Methods: We conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls. Results: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95% confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction <.01). Conclusions: Adiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.

AB - Background & Aims: Abdominal obesity and increasing body mass index are risk factors for esophageal adenocarcinoma and its main precursor, Barrett's esophagus; however, there are no known biological mechanisms for these associations or regarding why only some patients with gastroesophageal reflux disease develop Barrett's esophagus. We evaluated the association between Barrett's esophagus and multimers of an adipose-associated hormone, adiponectin. Methods: We conducted a case-control study evaluating the associations between adiponectin (total, high-molecular-weight, and low-/medium-molecular-weight) and Barrett's esophagus within the Kaiser Permanente Northern California population. Patients with a new diagnosis of Barrett's esophagus (cases) were matched to patients with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to population controls. Results: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls, and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett's esophagus among patients with GERD (total adiponectin fourth vs first quartile odds ratio [OR], 1.96; 95% confidence interval [CI], 1.17-3.27; high-molecular-weight adiponectin OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI, 1.33-3.56), but not compared with population controls. The associations were significantly stronger among patients reporting frequent GERD symptoms and among smokers (P values interaction <.01). Conclusions: Adiponectin levels are associated positively with the risk of Barrett's esophagus among patients with GERD and among smokers, but not among population controls without GERD symptoms. Higher adiponectin concentrations either independently may contribute to the aberrant healing of esophageal injury into Barrett's esophagus or be a marker for other factors.

KW - Adipokines

KW - Adiponectin

KW - Barrett's Esophagus

KW - BMI

KW - Esophageal Adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84947488112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947488112&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2015.01.009

DO - 10.1016/j.cgh.2015.01.009

M3 - Article

C2 - 25632808

AN - SCOPUS:84947488112

VL - 13

SP - 2256-2264.e3

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 13

ER -